Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399589 | 1.00 | CA2 (0.43) | CA2MAPK14CCNKCDK12F2RL3 | |
| SCHEMBL12654059 | 0.88 | NUDT1 (0.46) | CA2MAPK14CCNKCDK12F2RL3 | |
| SCHEMBL6394748 | 0.87 | CA2 (0.44) | CA2MAPK14CCNKCDK12KCNJ5 | |
| SCHEMBL6397888 | 0.87 | CA2 (0.41) | CA2MAPK14CCNKCDK12F2RL3 | |
| SCHEMBL17768005 | 0.83 | CA2 (0.43) | CA2MAPK14CCNKCDK12F2RL3 | |
| SCHEMBL17767915 | 0.83 | CA2 (0.43) | CA2MAPK14CCNKCDK12F2RL3 | |
| SCHEMBL17767918 | 0.83 | CA2 (0.43) | CA2MAPK14CCNKCDK12F2RL3 | |
| SCHEMBL14896744 | 0.82 | CA2 (0.43) | CA2MAPK14CCNKCDK12F2RL3 | |
| SCHEMBL17768163 | 0.82 | NUDT1 (0.44) | CA2MAPK14CCNKCDK12F2RL3 | |
| SCHEMBL14881706 | 0.82 | NUDT1 (0.44) | CA2MAPK14CCNKCDK12F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406911-B1 | 6-[2-(PHOSPHONOMETHOXY)ALKOXY] PYRIMIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 2016-01-06 | — | — | EP | disclosed |
| US-20050038058-A1 | Novel compounds and methods for therapy | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY | 2005-02-17 | — | — | US | disclosed |
| US-6818633-B2 | Antiviral for RNA or DNA viruses such as HIV, HBV or HSV; acyclic pyrimidine nucleoside phosphonate analogues; 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine; ; alkylating the 6-hydroxypyrimidine base with a dialkyl 2-chloroethoxymethylphosphonate | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2004-11-16 | — | — | US | disclosed |
| EP-1406911-A1 | 6-[2-(PHOSPHONOMETHOXY)ALKOXY]PYRIMIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2004-04-14 | — | — | EP | disclosed |
| US-20030109499-A1 | Novel compounds and methods for therapy | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ACADEMY OF SCIENCES | 2003-06-12 | — | — | US | disclosed |
| WO-2003002580-A1 | 6-`2-(PHOSPHONOMETHOXY)ALKOXY PYRIMIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038058-A1 | Novel compounds and methods for therapy | ZC3HAV1, IFNAR1, EIF2AK2 | CA2 4682/4885MAPK14 4060/4885CCNK 810/4885 |
| US-20030109499-A1 | Novel compounds and methods for therapy | IFNAR1, ZC3HAV1, EIF2AK2 | CA2 4666/4885MAPK14 3343/4885CCNK 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.